Activity Overview
This online, on-demand virtual symposium brings together renowned experts in HR+/HER2– metastatic breast cancer (MBC). In this educational program, these experts discuss the latest advances in integrating oral SERDs and emerging combination strategies into the care of patients with HR+/HER2– MBC. Through interactive, case-based discussions, participants gain practical strategies for treatment selection and sequencing, choosing between monotherapy and combination approaches based on patient-specific factors, applying clinical trial and real-world evidence, and proactively managing adverse events to optimize patient outcomes.
This educational activity is an archive of a live webcast held on June 25, 2026.
Target Audience
This educational program is primarily directed toward a global audience of community-based medical oncologists, surgical oncologists, advanced practice providers, nurses, and other health care providers involved in the treatment of MBC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Identify approved and emerging oral SERDs for the management of HR+/HER2– breast cancer
- Assess emerging clinical trial and real-world evidence to gain practical insights into the appropriate use of oral SERD-based treatment strategies for patients with HR+/HER2– MBC
- Integrate clinical trial data, real-world evidence, and patient- and disease-specific factors to inform personalized treatment decisions for patients with HR+/HER2– MBC
- Apply evidence-based approaches to anticipate, monitor, and manage adverse effects associated with targeted therapies for patients with HR+/HER2– MBC
Aditya Bardia, MD, MPH, FASCO
Professor of Medicine, Geffen School of Medicine
University of California, Los Angeles
Program Director, Breast Medical Oncology
Assistant Chief of Translational Research, Division of Hematology-Oncology
Director of Translational Research Integration
UCLA Health Jonsson Comprehensive Cancer Center
Los Angeles, CA
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: Alyssum, AstraZeneca/Daiichi Sankyo, Bristol Myers Squibb, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, Vyome; Grant/Research Funding: AstraZeneca/Daiichi Sankyo, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, OnKure, Pfizer
Bachar Samra, MD
Hematologist-Oncologist
Kelsey-Seybold Clinic
Adjunct Clinical Assistant Professor
University of Houston College of Medicine
Houston, TX
Disclosures: Advisor, Consultant, Fee for Service: AstraZeneca, Incyte, Pfizer
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
